Status:
COMPLETED
Can RIC Prevent Deterioration to Critical Care in Covid19
Lead Sponsor:
Derek Yellon
Conditions:
Covid19
Ischemia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The coronavirus disease (COVID-19) emerged in late 2019 and has since been diagnosed in over a million persons worldwide. As this virus progresses, it causes an extreme and uncontrolled response from ...
Detailed Description
COVID-19 has an early phase and a late, with rapid progression to ARDS (due to cytokine storm), multi-organ failure and death. Suppressing these cytokine elevations maybe a key to improved outcomes. A...
Eligibility Criteria
Inclusion
- \- Adult patients (aged 18 - 80 yrs) with diagnosed COVID-19.
Exclusion
- Contraindication for the use of a brachial cuff on either arm.
- Intercurrent disease with an expected life expectancy of less than 24 h, cardiac arrest, - Pregnant or breastfeeding women.
- Bleeding disorder or platelet count below 50.
- Currently enrolled in another research study
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04699227
Start Date
January 15 2021
End Date
October 31 2021
Last Update
November 29 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Atherosclerosis and Vascular Biology laboratory, State University of Campinas
Campinas, Brazil
2
Groote Schuur Hospital and Faculty of Health Sciences, University of Cape Town
Cape Town, South Africa
3
Royal Free London NHS Foundation Trust,
London, United Kingdom, NW3 2QG
4
East and North Hertfordshire NHS TrusEast and North Hertfordshire NHS Trus
Stevenage, United Kingdom, SG1 4AB